Synthetic peptide V11A reduces bacterial load and inflammation in pneumococcal meningitis

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Pneumococcal meningitis is worsened by bacterial lysis, increasing inflammation and host cell damage.
• Current bacteriolytic antibiotics exacerbate inflammation, creating a need for alternative treatments.
• A previously discovered peptide, V11A, demonstrated bacteriostatic and species-specific inhibition of S. pneumoniae in vitro.

Purpose of the Study:

• To evaluate the efficacy of peptide V11A in reducing S. pneumoniae growth and inflammation in relevant models.
• To assess V11A's therapeutic potential as a non-bacteriolytic antimicrobial for pneumococcal meningitis.

Main Methods:

• Peptide V11A was tested against S. pneumoniae in human cerebrospinal fluid (hCSF) from healthy donors and a meningitis patient.
• An infant rat model of pneumococcal meningitis was used to assess V11A's in vivo efficacy.
• Bacterial load, cytokine levels (GRO/KC/CINC-1 and IL-10) in CSF were measured.

Main Results:

• V11A reduced S. pneumoniae growth in both spiked hCSF and naturally infected hCSF.
• In infant rats, V11A decreased bacterial counts in CSF and blood.
• V11A treatment led to reduced concentrations of inflammatory cytokines GRO/KC/CINC-1 and IL-10 in the CSF.

Conclusions:

• Peptide V11A shows potential as a therapeutic agent for pneumococcal meningitis.
• V11A can reduce bacterial burden and mitigate the inflammatory response associated with the infection.
• This study supports the development of V11A as a non-bacteriolytic antimicrobial alternative.